American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

(2010) J Glaspy et al.   BRITISH JOURNAL OF CANCER

Role of recombinant human erythropoietin in patients of advanced cervical cancer treated by chemoradiotherapy

(2010) Seema Gupta et al.   CANCER BIOLOGY & THERAPY

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)

(2009) P. L. Greenberg et al.   BLOOD

Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

(2009) Johan Vansteenkiste et al.   BMC CANCER

Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis

(2009) M. Tonelli et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Initiation of epoetin-α therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy

(2009) John A. Glaspy et al.   CANCER

An assessment of erythroid response to epoetin α as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach

(2009) Suneel Mundle et al.   CANCER

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia

(2009) Enrique Hernandez et al.   CURRENT MEDICAL RESEARCH AND OPINION

What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?

(2009) Matti Aapro et al.   EUROPEAN JOURNAL OF CANCER

Weekly Administration of Epoetin Beta for Chemotherapy-induced Anemia in Cancer Patients: Results of a Multicenter, Phase III, Randomized, Double-blind, Placebo-controlled Study

(2009) Masahiro Tsuboi et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Effect of Epoetin Alfa on Survival and Cancer Treatment–Related Anemia and Fatigue in Patients Receiving Radical Radiotherapy With Curative Intent for Head and Neck Cancer

(2009) Peter J. Hoskin et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care

(2009) Neal J. Meropol et al.   JOURNAL OF CLINICAL ONCOLOGY

Patterns of Use and Risks Associated With Erythropoiesis-Stimulating Agents Among Medicare Patients With Cancer

(2009) Dawn L. Hershman et al.   JNCI-Journal of the National Cancer Institute

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

(2009) Julia Bohlius et al.   LANCET

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

(2009) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review

(2008) Nadine Shehata et al.   ANNALS OF HEMATOLOGY

Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis

(2008) Victor Moyo et al.   ANNALS OF HEMATOLOGY

Tumor Progression Associated with Erythropoiesis-Stimulating Agents

(2008) Ashley M Newland et al.   ANNALS OF PHARMACOTHERAPY

Prevention of anaemia by early intervention with once weekly epoetin alfa during chemotherapy

(2008) J.H. Schouwink et al.   EUROPEAN JOURNAL OF CANCER

Erythropoiesis-Stimulating Agents in the Treatment of Cancer-Associated Anemia—Reply

(2008)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia

(2008) Charles L. Bennett   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

(2008) Robert E. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia

(2008) Laurent Bastit et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa

(2008) Paolo Pedrazzoli et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer

(2007) Gillian Thomas et al.   GYNECOLOGIC ONCOLOGY

Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update

(2007) J. Douglas Rizzo et al.   JOURNAL OF CLINICAL ONCOLOGY